Rockville, MD The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.
Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria i.e., a vision field test as the primary functional outcome measure.
However, new technologies that assess abnormalities and changes in the optic nerve structure and its function offer vision researchers alternative pathways to better diagnose and treat glaucoma.
This symposium will focus on new outcome measures appropriate for evaluation of glaucoma therapies. The aim is to encourage the development of new glaucoma therapies, facilitate their evaluation and ultimately benefit patients.
Attendees will include:
Registrants will be able to submit questions/comments in advance through a link on their registration confirmation notice.
Glaucoma a potentially blinding but treatable group of diseases affects 2.2 million Americans age 40 and older, resulting in direct medical costs of $2.86 billion annually.
|Contact: Lancey Cowan|
Association for Research in Vision and Ophthalmology